Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Orthocell Ltd ( (AU:OCC) ) has shared an update.
Orthocell reported its seventh consecutive quarter of record revenue, posting $3.2 million for the December 2025 quarter, up 45% year on year, driven by accelerating adoption of its Remplir nerve repair device and initial US sales. Backed by $49.4 million in cash following a heavily supported $30 million capital raising, the company is ramping up global commercialisation of Remplir with a distributor network now covering more than 25 US states, early traction in Canada and Hong Kong, and a regulatory application lodged for entry into the sizeable EU and UK nerve repair markets; it also secured global distribution rights to PearlBone bone regeneration technology and is building a new commercial opportunity in nerve-sparing prostate cancer surgery that could expand its US addressable market to about US$2 billion.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is an Australian regenerative medicine company focused on advanced surgical products for nerve and tissue repair. Its lead product, Remplir, targets the global peripheral nerve repair market, with a growing commercial footprint in the US and planned expansion into Canada, Hong Kong, Europe and the UK, while the company also pursues opportunities in bone regeneration through its investment in PearlBone technology.
Average Trading Volume: 630,783
Technical Sentiment Signal: Buy
Current Market Cap: A$271.3M
For detailed information about OCC stock, go to TipRanks’ Stock Analysis page.